Amneal Pharmaceuticals, Inc. AMRX Non-cash interest expense
Non-cash interest expense at other companies
Other financials
Where this comes from
Reported directly by Amneal Pharmaceuticals, Inc. in its filing.
Tagged under the XBRL concept us-gaap:AmortizationOfFinancingCostsAndDiscounts.
The official record: Amneal Pharmaceuticals, Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Amneal Pharmaceuticals, Inc.'s non-cash interest expense.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Amneal Pharmaceuticals, Inc.'s non-cash interest expense?
- Amneal Pharmaceuticals, Inc. (AMRX) reported non-cash interest expense of $3.89M in Q1 2026.
- How has Amneal Pharmaceuticals, Inc.'s non-cash interest expense changed year-over-year?
- Amneal Pharmaceuticals, Inc.'s non-cash interest expense decreased by 42.9% year-over-year, from $6.81M to $3.89M.
- What is the long-term trend for Amneal Pharmaceuticals, Inc.'s non-cash interest expense?
- Over 4 years (2021 to 2025), Amneal Pharmaceuticals, Inc.'s non-cash interest expense has grown at a 24.9% compound annual growth rate (CAGR), from $9.2M to $22.43M.